Document jmD72k9OmLeKBVO8B22V2dX4O

AR226-2771 FOR DU PONT PSE ONLY E. I . du Pont de Nemours & C o ., I n c . H askell L aboratory fo r Toxicology nj In d u s tria l M edicine E lk to n Road, P. 0* Box 50 Newark, Delaware 19/11 HASKELL LABORATORY REPORT NO. 593-31 M aterial T ested O ctanolc a d d , p en tad ecaflu o ro -, ammonium s a l t * H askell No, 14,045 & 12,037 Study In ltla te d /C o a o le te d 5 /1 8 /8 1 -6 /9 /8 1 _ M aterial Subm itted by Polymer Products Department W ashington Works*I AMMONIUM PERFLUOROOCTANOATE BLOOD LEVELS IN THE FEMALE SAT I. ' SUMMARY: To e v a lu a te th e o v e r a l l h e a lt h im p lic a tio n s o f th e v a r io u s b i o l o g i c a l e f f e c t s produced by ammonium p e rf lu o ro o c ta n o a te (C -8) , a s e r i e s o f s t u d i e s was u n d e rta k e n to m easure C-8 l e v e l s I n whole b lo o d a s a f u n c tio n o f a number of v a ria b le s in clu d in g ro u te o f a d m in istra tio n , tim e follow ing a d m in is tra tio n , and number o f tre a tm e n ts . Most work has been conducted In th e m ale r a t b u t p o s s ib l e t e f a to g e n i c e f f e c t s o f C-8 le d to e x te n d in g rM work to the fem ale r a t and p a r tic u la r ly to the pregnant r a t . The u p ta k e and c le a r a n c e o f C-8 from th e blood o f fem ale r a t s fo llo w in g a s in g le o .u l dose was ra p id w ith the peak reached 1-2 hours p o st-tre a tm e n t a d w ith v i r t u a l t o t a l c le a ra n c e by 24 h o u rs. A d o se -re sp o n se was d e m o n stra te d w ith no ap p aren t: changes I n blood C-8 l e v e l s fo llo w in g m u ltip le o r a l d o sin g . The slow er c le a ra n c e r a te in male r a t s was dem onstrated follow ing a sin g le o ra l dose. The same g e n e ra l sta te m e n ts apply fo llo w in g I n h a la tio n e x p o su re . A s i n g l e 6-h o u r I n h a l a t i o n ex p o su re r e s u l te d i n peak blood l e v e l s w ith in 1 hour a f te r c e ssa tio n of exposure, the m aterial rap id ly cleared from th e blood, the number o f exposures d id not a f f e c t b lood,le v e ls , and male r a ts c le a re d the compound much more s lo w ly . P re g n an t and n o n -p re g n a n t r a t s showed s im ila r C-8 blood l e v e l s fo llo w in g e ith e r o ral or in h alatio n exposures. - 1- Company Sanitized. Doss not contain TSCA CBI th e anount of C,, -8,, present M ehe tra ia h t chain .tra lg ^ ^ isomer in crease follow ing 0-8 r e la tiv e to the o o o - a t r a i g h t ^ a l laoma ,,o n -straig h t chain lsoeere 3 3BS *- * "* -- l""r01 t h a t a m e ta b o lite 1 p r s e n te INTRODUCTION: I n p e rflu o ro o c ta n o a te (C -8), the * 3 " t S "I s l * a lb in o ^ fl^ o a c u te ix fc ^ atio n C r l :C0* r a t ( u b a c u te ^ ^ y ^ ^ ^ T o i c i t y ( r f T I th e t o x i c i t y W B ^ f l ^ J J J W ^ J * wcre determ ined to o b tai c o rre la tio n s subacute s tu d ie s b lo o d * iev ej o* Company and a t H a s k e ll w ith b io lo ^ c a l e f f y tso a d la tS c t d ifferen ce in the excretory S T t f C ^ T T S a n d f ^ g h 1i * n ih 5 S .) SS u e '? h e Ci ! ^ " * e e d t h e S K T S i S ? " 2 a^ ceso lc, c irc n la tin g la v e la of C-8, -- * S S H e ! . . ace unnald.rnbly higher in eel* t e . te t, in ap ite o f jh le ^ f e S S e ) 5 5 r 3 l S TM * C-8 i n th e r a t a r e s i m i l a r ( I f b o vaaue , f o f c _8 m th e r a t w ere h t " ! finder Study o* 1-2998 CoC in P r e n a n t feMlr r j ex r r i t s s s t z *m s s t t v ariables: *| ! ^ S ^ S f t A n of poet-eipoeure t in . folloning o ra l - i .i n i .t r .t i o n b) m u ltip le versus sin g le doses c) fu n ctio n of poet-exposure tim e ^ ^ ^ r i n g in h ala tio n exposure b) nose response c h a ra c te ris tic s f i e v e i a * pr e s n a n t v e ts u s a a ' p re g n a n t r a t s b) o ra l exposure and in h ala tio n exposure gOCEDORE: A. Animals Female albino ^a t 3 '^ " ^ ^ g r a v i d ! f e S e w e i g h i n g approxim ately 200 ipproximately 200 g; pregnan ^P g weighing approxim ately 250 g ;;re" t u i S d T S f S i , ' d1"8 Labor" o t l e s ' * " (C rl - 2- l i b i t u m . The . - t a Cih _ ;__ ^ ,, l i a b i l i t y f o r 1 e* Pr su p p lier) were observed for generax B ^ r <i A dw iniitratioP _ Fot -- solutions (0.03-2.0*). Inhalation P J . hrough a 2- s ta g e g la s s L i 5 ^ ~ * i w r -S n c e n tr a tio n s w ere determ ined b o t h g r * J J lb e r f i l t e r s . Type AB. 25 a t C` Blood p -- enr H P_ p u n c tu r e . Whole Blood sam p les *r e o b ta J " d f j " a M t te d t o ^ D f o r c h e m ic a l a n a l *!,i * blood samples were " g z j t t determ ine C - B ^ c o n c e n t r y i ^ L ^ A P j ^ te p o rt Dated 9 /1 6 /8 1 ). t o nte d ^ ^ ? S S 5 n t a Crongs Group A D o .. 25 / . O r a lly . 3 f -- sacrificed " *" 8" " P ' Ai A-2 A-3 A-4 A-3 -6 A-7 Group B 1/4 hour a f te r dosing 1/2 hour a f t e r dosing 1 hour A fter dosing 2 hours a fte r dosing 4 h o u rs 'a f t e r d o s in g 8 hours a fte r dosing 24 hours a f te r dosing 2.5 / * o r a l l y . 3 1 r a t . 0 * r o u ,. a a c r l f l c * B-l B-2 1/2 hour a f te r dosing 2 hours a fte r dosing 8 hours a f t e r d o sin g B-3 24 h o u rs a f t e r d o sin g B-4 - 3- ntainTSCACB! ,not co impany Sanitized. Dce` en /v ,, a i l * 3 fe n a le r a ts per group, s a c r ific e d Group C Dose 150 mg/kg o r a U y , J C -l C-2 C-3 C-4 Group D 1/2 to u r a fte r dosing 2 hours a fte r dosing 8 to u rs a fte r dosing 24 h o u rs a f t e r dosing _ . ,, . y , orally a * toy. Do. 11 4J* " J group, then sacrificed 3 " " l e *" D -l D-2 D-3 D-4 D-5 0*6 D-7 1/4 t o u r a f t e r 11t h d o se 1/2 h o u r a f t e r 11t h d o se 2 tours a f t e r U t h dose 4 hours a f t e r 11t h d o se 8 tourS a f t e r 11t h d o se 24 to u rs a f t e r U th dose 115608 t o u r s a f t e r l l t h d o se Group B E -l E-2 E-3 E-4 ... - U . 3 - 1* 1/2 hour a f te r dosing 8 hours a fte r dosing 24 to u rs a fte r doeing 168 hours a f t e r d osing gI0a" " " ^ Oc0up , . v li Pr to /M . I * 3 * 1/4 hour a f t e r exposure P-1 F-2 F-3 F-4 1/2 hour a f te r exposure 1 hour a fte r exposure tasar a fte r exposure hours a fte r exposure r-5 F-6 F-7 F- 8 8 24 168 tourS a fte r exposure hours a fte r exposure to u rs a fte r exposure Group G Exposure v ia in h a la tio n , fem ale r a ts per group, a a c rif 1 G-l G-2 1/2 hour a f t e r exposure 2 to u rs a fte r exposure 8 hours a fte r exposure G-3 24 hours a f t e r exposure G-4 3 ln g l* sin g le exposure, ' - 4aapWi Saoiltee' v.ain i SCACD Group , Exposure w . ^ 3 fe a a le ra ts per group, sa crifice d H -l H-2 H-3 H-4 Group I 1/2 hour a fte r exposure 2 hours a fte r exposure 8 hours a fte r exposure 24 h o u rs a f t e r ex p o su re Exposure v ia in h a la tio n , 6 h r/d ay , mala r a ts p er group, s a c rific e d 10 m g /v f , s in g le exposure, 1-1 1-2 1-3 1-4 1/2 hour a f t e r exposure 2 hours a f te r exposure 8 hours a fte r exposure 24 h o u rs a f t e r exposure 3 pregnant ra ts per Group J Dose 25 a g /k g o r a l l y , g e s ta tio n day 15, gxoup, sa c rific e d J-l J-2 J-3 1/2 hour a f t e r dosing 2 hours a fte r dosing 8 hours a fte r dosing J-4 24 to u rs a f te r dosing pregnant ra ts per group, saerx* ^ 6 u*3 K.-1 K-2 1/2 h o u rs a f t e r 6th dose 2 to u rs a te r 6th dose Group u Dose 25 / g / d w o r a l l y , <U7* 6 pregnant ra ts per group, sacrificed 15> L -l L-2 L-3 L-4 ** 1/2 h o u r a f t e r 10t h dose 2 hours a f t e r 10t h dose 8 hours a f t e r 10t h dose 24 h o u rs a f t e r 10t h dose S 5 ' " 2* " PO' r ' MM_-1l 1/2 h o u r a f t e r ex posure HM --22 2 h o u rs a f t e r ex p o su re - 5- Sahv ;otPa^ ^SC ^C0V 0 mg/n3 , gestation days 6 Group v is inhalation, N Exposure through 15, 3 pregnant ra ts 6 hr/day, per group, sacrifice 1/2 hour after 10th exposure TSm.TS AW) COHCLBSIgS. ,, u ,, la ltt rat blood e re as *11 as the percent ibtained are discussed belo*. - , . . . . /-a le v e ls as a fu n ctio n or tinw o o r a l adm inistration, female r a ts , --8 lev post-dosing (see Figure 1) C-8 le v e ls o f 30 P P ^ at 1 S S S K t s a r - ' - s s i - v ? "- - " " , e-B le v e ls as a function of dose o o ra l adm inistration, female r a ts , (see F ig u re 2) l62 C-8 le v e ls a t 1/2 hour fo U 0 ! " ^ " ^ " S' m d o e. r e e f o " ppm, doses adm ^iatered . ^ valu es ranging from 0.1 2 ( 2 . as seen a t 24 hour The response was lin e a r . _ . 1 - i 1i u S f u i - S T rela ted to t b . ^ administered orally , mXa id f - l e r e t s t o ll o in g . e lo g le o t l do o O ral a d m in istra tio n r mal o f 25 mg/kg (s F ig u re 3) C-8 le v e ls in female ra ts were 16 ppm < ( i ea'hours J ^ T h e coirSreTspoo.nTdinpgpmvalue, f o r m ale r a 6 3 , 50. and 23 PP- r bo^ creatffletit* . C-8 le v e ls as a fu n ction of number o o r a l adm inistration, female r a ts, C 8 le of doses (Figure 4) _ -r- a lM d l . l , i o / e ^ e r e ts *r t . sot 17 p m , 1 sod 11 doses r e sp e c tiv e ly -6 6Company Sanitized. Dcos not contain TSCACBl V i ' - r r u r ^ - T s : < Si 14nd11do8esre8pectivel7* ^ - - s s " SS"- S S L S '. S S = & - * * . -- -- " dose rem aining co n stan t. C-8 levels as a function of time Inhalation exposures, feaals rats p o s t- e x p o s u re (s e e F ig u re 57 C -. i . v i . a 9. H . - ^ S T w i S S ^ S hour in h a la tio n e r p o a u r e t c lO^mg/ ro x la a te l 7 70 PP* 8 h o u rs, 100-110 ppm th ro u g h 1 h o , ^ dropped t o 0 .3 9 ppm f u r t h e r d e c re a s e d t o 5 PP* r a l p a tt e r n was s e e n in r a t s 168 h o u rs l a t e r . T his same g m g r a l ^ phase seen in o ra l exposed to e ith e r 0.1 j/ h l ^ d saap lin g follow ing a S S - V S <* " " ***otal 40" * ` given, finite time). is In h a la tio n eatposures, fem ale ra ts (see Figure 5) - of C-8 le v e ls as a fu n c tio n o f dose C-8 le v e ls a t 1/2 hour exposure ranged from 2 to 10 mg/ 69 ppm ), 8 * Jrborne M n c e n tra tio n so f J>. i ^ seen a t 2 hours U , *' 4 71 ppm) and 24 h o u rs ( 0 .1 4 , ;5' 5Jhe re s p o n d in g t o 0 . 1 , 1, and 10 mg/m The 0 .9 9 9 ). w <-- * - ^ ici" e o . f r- S S ? .S 5 5 lf 2 * . c l--- ^n, m A fem ale r a t s fo llo w in g a s i n g l e 6 h o u r S S a S S T S J i * - (T able, Groups F and I ) C-8 le v e ls 1* f - * > . bcoorurrees)p,on71dinr ga . v alu e s f o r m ale ra t- "" 1 . 1W . * " > 147 - 7Company Sanitized. Does not contain TSCA CH 4 ore u n t and non-pregnant fem ale r a t a , C-8 O ral a d m i n i s t e r a t i o n t P J J J 11 (Figure 6) lev els follow ing a single o ral ' C-8 l e v e l s i n b o th * l s i n g l e 25 ngA S o r a l * 2 n o u r 8 , 26 and 31 PP a t 8 & c ^ u d .. c * - " - 1 d " i a a " pregnant v s. non-pregnant ra ta . " " <> r --a l e v e l s a s a f u n c t i o n ( sr er E " *: - * a ts aiv en e it h e r 1, 6 o r 10 d o a e a j Blood le v e ls in pregnant r a ts giv follow ing the la s t 0-8 r . 18, U . ri " h lo * concentration, in the 2 7 C ? 0 2 m <15 ssi.=s r.^ % o u o r - s t s is s ." s s w - - * - -- - ~ ie - d ifferen t. .- . a*ar to accum ulate i n th e blood or p r e g n a n t5rats^ fo llo w in g re p e a te d o r a l o r i n h a l a t i o n expos 0 The r e l a t i v e amount of ^ s t r a i g h t - c h a i n C-8 b e in g S n l , 4 and 8 exposure, fem ale r a ts s t r a i g h t - c h a i n C-8 (aro u n d 9 0 1/* FoU ow ing^nhalation re la tiv e ly high percent of a fte r exposure. Jb* w c o lle c te d remembering .h a t probably re f ie c ts t ^ P o i n ^ 11^ r a t has been inhaling ^ o h^ a p r io r to bein g sampled a t the clearance of l e a n t i n e a p o . t - p o o " . Xn ^ * " " ; r t t h 73-872 hoing L n - . t t . l i h t chain p n .t-.ra l id 76-822 a t r a l g h t - c h a i n 2^ 2 S o i> p o .t- ln h a l.tio n p n n n te . s t r a i g h t - c h a i n 1/2 t o no cccci.d .1 r s u s a s s s . " *" - fe" ie 8- - Sanitized. Doss not contain TSCA CB! C om paq * Synonyas: A m onlua perfluorooctanoate C-8 ^ ^ Technician Work Supervised hys 0 , Louis D a8hiell Supervisor Study D irec to r/R e p o rt P repared by Section Supervisor | A cute Investigations GLK:tac:HP:4.6 . Da t e I s s u e d : D e c e n b e ^ J W l , p o rt No. 593-81 9 Company Sanitized. Does not contain TSCACBt TABLE # Uu e s Aunduioo oo H3.' -aHt o > oa TABLE (C o n t.) /tu^duioO Route o f Dose . Group Sex A d m in is tra tio n (m g/kg) (mg/m ) 1-1 M 1-2 M 1-3 H 1-4 M J=1 BgP J - 2 PgF J - 3 PgF J - 4 PgF K -l PgF K-2 PgF h -l PgF L-2 PgF L-3 PgF L-4 PgF H-l PgF M-2 PgF N -l PgF Control F Inh. Inh. Inh. Inh. O ral------ ------- Oral Oral Oral 25 25 25 25 Oral O ral 25 25 O ral O ral O ral O ral 25 25 25 25 Inh. Inh. Inh. 10 10 10 10 ---- . ..... - 10 10 10 TABLE ( C o n t.) Number o f Semple taken C-8 Blood L evel Doses o r (h o u rs follow ing (ppa) E xposures l a s t d o a e /e x p o s u re ) Mean Range Straight-C hain C- 8 <*> 1 1 1 1 r .............. l l l 6 6 10 10 10 10 1 1 10 -- 1/2 2 8 24 m 2 8 24 1/2 2 1/2 2 8 24 1/2 2 1/2 137 118-163 157 114-203 182 170-198 147 143-151 18 14-21 39 34-44 31 29-33 22 12 5-16 37 28-35 12 9-15 15 11-17 11 9-13 1 1-2 77 66-91 90 86-96 53 45-67 0-0.008 0.0-008 76 76 79 82 81 82 89 -- 78 82 80 83 -- 88 88 8B - O-28 MO/KO -- - FIGURE 2 blood levels in PPM FIGURE 3 TIMF FIGURE 4 " i w>w*a"""10j_8 blood LEVELS IN PPM FIGUR** A 10 -8 BLOOD LEVELS IN PPM FIGURE 6 NOMPME0 0*>PMONANT tv II W APPENDIX A cc: E , du P o n t d eT u m o j j r s & C o m pa n y ' UU ' wewi** _ Wilmington, Dela w a re 19898 m l m pnooucts department xrcpiMtx;*- tat.on September 16. 1981 m tb lm ik a tio of .S S ^ M S s a s r iB K a 181 Iat in a As p a r t of T_ J E ,S i2 .rS SSCR* ^ - S f " e b ..n d rle i to r *, - * * 191 s" *'1** f H ialyzed a t t h i s tim e ). oroCedure described L,n, t v,e gas chromatographic P , noted report6 (le tte r o T l ^ / B l ) ; ^ t a i l s ^ e ^ e n j isom ers). For most of t P ^ l n th e t 8b l e s . . as describbeed e a r lie r , and i s win cliu r e s u lt s and s ^ e id e n t..if i.c a t ion ffnorr Cthhfei tthl r ---------- . Bg<ivven min the attached tables as follow s. .... Table 1 T ab le 2;' __OT_n_r a_hlf-,ltllaSotlnfoP.n ,^S_jgl n^gpnilpealase ^subabmrmr axintitsteieadd obyy - g roup aanndd Table Tables eSTs R esufts f o r ^ ^ V f ^ ^ L "5 Taabl.es 9*10; R esults f o r ^ ^ ^ y ts" e ' s . S. Stafford A ttachm ents8 ^ jah Key Words:: l ^ ^ ^ r f s i o o d Analysis, mpany Sanitized. Does not contain TSCA City P erflu o ro o ctan o ate ^^^* } doing something about There's * world ol thinfls we're kxvdvioO COTM Sample (a)_ 81-2047 81-2048 81-2049 81-2050 81-2051 81-2052 , 81-2170 8 1 -2 IT I **8 1 - 2 1 7 2 81-2173 nat- Received 5/15/81 5/15/81 5/15/31 5/15/31 5/15/81 5/15/81 5/20/81 ' 5/20/81" 5/20/91 5/20/81 Jr KO1> 81-2174 1 81-2175 5/20/81 5/20/81 Cfl 3. No" 3 oo c o2 . 'i -1 81-2176 81-2177 81-2178 81-2179 81-2130 81-2131 81-2182 81-2133 81-2184 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 taule 1 # ORAL 303125 303126 303127 303128 303129 303130 303131 - 5 0 3 1 3 2 ------------ 303133 303134 303135 303136 303137 303138 303139 303140 303141 303142 303143 303144 303145 f,c A nalysis (b ). 11 II ll II II II III HI III 111 1/2 n r. 1/2 h r. 1/2 Hr. 2 hr8. 2 hrs. 2 hr8. 1/2 h r. 1 /2 h r . ------------1/2 h r. 2 hrs. 7 /1 0 /8 1 ,c 7/ 10/ 81,c 7 /1 3 /8 1 ,c 7 /1 4 /8 1 ,c 7/l4/81c 7/14/81.C 7 /1 7 /8 1 ,c -----7-/l7/8LrC 7 /1 7 /8 1 ,c 7/13/81,p A 7 /l5 /8 l,c III 2 hrs. 7/13/81,P 8 7 /i5 /8 1 ,c III 2 hrs . 7 /1 3 /8 1 ,P 4 7 /1 5 /8 1 ,c III 8 hrs. III 8 hrs. III 8 hrs. I I I 24 h r s . I I I 24 h r s . I I I 24 h ra . 1 1/2 h r. I 1/2 h r. I 1/2 h r . 7 /1 0 /8 1 ,p 7 /1 0 /8 1 .P 7 /1 0 /8 1 .p 7 /1 7 /8 1 ,p 7 /1 7 /8 1 ,p 7 /1 7 /8 1 ,p 7 /1 7 /8 1 ,c 7 /1 7 /8 1 ,c 7 /1 7 /8 1 ,c -- v - ------------- X S t r a i g h t - 1. tie F / r blood 16 C h ain Cn 77 5 .4 (c ) 79 16 78 45 83 39 81 28 83 11 80 ,, 8 . 7 .............* -- - .......... 3 k ___ 15 79 16 16 83 12 11 83 17 17 83 10 * 13 9 .2 0.70 .7 1.5 90 21 18 77 77 14 rnurF.NTRATION TM PERFliUOROOCTANOATjl _IH RAT BLOOD SAMPLES^j j p ^ o i i A L Sample (a ) ---- --- --- - -- PRAL NO. 11-2135 81-2186 81-2187 81-2188 nate Received 5/20/81 5/20/81 5/20/81 5/20/81 81-2189 81-2190 5/20/01 5/20/81 81-2191 81-2192 81-2193 81-2053 81-2054 81-2055 81-2056 81-2057 5/20/81 5/20/81 5/20/81 5/15/81 5/15/81 5/15/81 5/15/81 5/15/81 D eglR w atln! Ra t ff, CrouBi, Recovery Time 303146 1 2 hrs. 303147 1 2 hr 8. 303148 1 2 hrs. 303149 1 8 hrs. 303150 303151 1 8 hrs. 1 8 hrs. 303152 303153 303154 C o n tro l #1 C o n tro l 92 C o n tro l #3 C o n tro l #4 C o n tro l 05 1 24 h r Si ...... I 24 h r s . 1 24 h r s . CC A nalysis (b) V n a te Analyzed e n . U8| F / r blood 7 /1 4 /8 1 ,c 34 7 /1 5 /8 1 .c 44 7 /1 4 /8 1 ,c 40 7/10/81,c & 7/10/B l.p 31 361 33 7 /1 0 /8 1 ,p 7/10/81.C & 7 /1 0 /8 1 .p 7 /1 7 /8 1 ,p 32 267 29 31 2.2 7 /1 7 /8 1 ,p 2 .3 7 /1 7 /8 1 ,p 2.5 7 /1 0 /8 1 ,p n .d . 7 /1 0 /8 1 ,p n .d . 7 /1 7 /8 1 ,p 7 /1 7 /8 1 ,p n.d. oO.OOB 7 /1 7 /8 1 ,p >%n . d . x S traight Chai.n_C, 81 82 82 88 90 usduioo iCnO 2. OpOooifl o** oo . 3 TABLE 1 Sample Designation for! l\<lO ral. A ll p reg n a n t fe m a le s , 25 tng/kg Sr0U! i i SS V s 0e9. : 24 h o u rs a p a r t A Z l S i. S ^ d o s e ; . 24 h o u rs a p a r t ^rouP H i. --------- in ^ Method es-567 b) ("D eterain atio n o f P e r f l u tfSlng perflu o ro -n -o c ta n o ic a id ^ a n a ly S i s Method" , S . S t a f f o r d . ' c a p i l l a r y column a n a ly s i s . t y P p i<ft standard and *i th e * p a^ e r che d a ta ) . R e su lts a re r p ^ perfluoro- is in d ic a te d by p ,, - a n ic f l u o r i n e a n a ly s e s (PP * Hone d e te c te d comparison with to al linit oro ^ f ^ F ^ w h i c h cannSfbe distinguished o(nct.adn.)oicis arceipdo;,rted f o r s..amplale*s wwxitthn *< 0.005 pp '* wniCU V " .' " " ,, t t J , " j a s i . - u . ' s s J : ^ TM J s r s . :n i s `' tS S W * 's s * i r rva#*comparable = ; SS5r 5-- *> in ternal standard. Company Sanitized. Does r.at contain TSCA CB1 -22- TABLE 2 INHALATION Of IN AT BUMP S 'P^ # Sample (a) PRAL No. 81-2323 81-2329 81-2330 81-2327 81-2328 nate Received 5/28/81 5/28/81 5/28/81 5/28/81 5/28/81 31-2334 81-2335 81-2336 81-2337 81-2338 81-2339 81-2340 81-2341 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 n a n lfin a tlo n i Rnt 302207 (A) 302302 (A) 302219 (A) 303259 303260 302197 302242 302284 302304 302335 302363 303261 303262 " - " T . RecOVerV T tgg days (6-15) days (6-15) days (6-15) c o n tro l c o n tro l day 15, day 15, day 15, day 15, day 15, day 15* c o n tro l c o n tro l 2 hrs. l/2 h r. 1/2 h r. 2 hrs. 2 hrs. 1/2 h r. n c A n a ly s is (b )------ -------- ^ Z Straight* nnra Analyzed 7 /1 5 /8 1 ,c 7 /1 5 /8 1 ,c 7 /1 6 /8 1 ,c 7 /1 3 /8 1 ,p 7 /1 3 /8 1 ,p , pfi F/B M S i 48 67 45 n .d . n .d . Chatn-^ 8 86 89 88 7 /1 6 /8 1 ,c 7/16/81.C 7 /1 6 /8 1 ,c 7 /1 6 /8 1 ,c 7 /1 6 /8 1 ,c 7 /1 7 /8 1 ,c 7 /1 3 /8 1 .P 7 /1 3 /8 1 ,p 87 75 91 96 86 66 n .d . n .d . 86 88. 86 88 89 90 /uedulOO - E 3 - (a) to I5.i N<0 a. ao (b) CO Sample D esignation for_ |wj in h a l a ti o n A ll p re g n a n t fe m a le s , 10 mg/jn . - In the ta b le , exposure on days 6-15 of g e s ta t or on day 15 o n ly . CC a n a ly s is a s d e s c rib e d in T ab le 1 , N ote (b) RESULTS FOR TABLE 3 fORAL). llg F/l() s r i? s :.T*s:& Control sample or b o c h j ^ l ^ or 24- RESULTS for TABLE 4 . _ (a) I TM * TM , m e n " ' TRATcm-CHAig-- a-- b le ! for capillary (a) r CstSi - the concentration. w l'*h ** "*nuBber* Company Sanitised. Does not contain TSCA CBI -2 5 - , 0^ IaO\ 1n ' *V3A<. Ca3O n' rJu Q oo no oo3 K3. 0o) > o 13 TAOLK 5 re n n KNTRATION OF PEUFLUOROOCTANOATE IN HAT BLOOD SAMI' Sample (a) PRAL No. 81-2122 81-2123 81-2124 81-2125 81-2126 81-2127 81-2128 81-2129 81-2130 81-2131 81-2132 31-2133 81-2134 81-2135 81-2136 81-2137 81-2138 31-2139 81-2140 81-2141 81-2142 81-2143 81-2144 rtni-p Received 5/20/81 5/20/81 (c) 5/20/81 5/20/81 5/20/81 5/20/81 (c) 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 (c) 5/20/81 5/20/31 5/20/81 5/20/81 5/20/81 5/20/31 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 (c) 5/20/81 D esignation: Hat 303199 303200 303201 303202 303303 303204 303205 303206 303207 303208 303209 303210 303211 303212 30321" 303214 303215 303216 303217 301218 303219 303220 303221 81-2145 5/20/81 303222 Group. Recovery Time 11 1/2 h r . 11 1 /2 h r . 11 1 /2 h r . II 2 hrs. II 2 hrs. II 2 hrs. II 8 hrB. II 8 hrs. II 8 hrs. I I 24 h r s . I I 24 h r s . I I 24 h r s . I I I 1/2 h r. I I I 1/2 h r. 111 1/2 h r . III 2 hrs. III 2 hrs. III 2 hrs. III 8 hrs. III 8 hrs. III 8 hrs. I I I 24 h r s . I I I 24 h r s . I I I 24 h r s . ORAL m l D ate A nalyzed lCfll . OS F/fi blood 7 /2 7 /8 1 ,c (d) 7 /2 7 /8 1 ,c <d) <d) (d) <d) (d) (d) 7 /2 4 /8 1 ,p (d) 7 /2 4 /8 1 ,p 7 /2 9 /8 1 ,c 7 /2 9 /8 1 ,c 7 /2 9 /8 1 ,c (d) (d) (d) 7/29/81.c 7/29/81,c 7 /2 9 /8 1 .c (d) 7 /2 9 /8 1 ,c 7 /3 0 /8 1 .P 7 /2 7 /3 1 ,c 7 /3 0 /8 1 ,p l.l - 2 .8 0 .1 3 0.11 102 162 , 223 - 131 178 162 V 20 20 15 15 X Straigl C hain C( 79 -- 81 * ** ** 79 79 79 ** * * 95 93 89 94 91 WJ Snmole (a) rKMU iw 81-2146 81-2147 81-2148 81-2149 81-2150 81-2151 81-2152 81-2153 81-2154 81-2155 f) * 8-3Oo3J 3I j HOOOo<a9) 81-2156 81-2157 81-2158 81-2159 81-2160 81-2161 81-2162 81-2163 Oo3*0*>*. 81-2164 81-2165 3 81-2166 a> o 81-2167 j*> ow 81-2160 81-2169 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/ 20/81 (c) 5 2 0 /8 1 5/20/B l 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 5/20/81 302494 302495 302496 303175 303176 303177 303178 303179 303180 303181 303182 303183 303184 303185 303186 303187 3 188 303189 303190 303191 303192 303193 303194 303195 AllW iiU ORAL Hcrnverv Time 1/2 h r. XV 1/2 h r . XV 1 /2 h r . I 1/4 h r. I 1/4 h r. I 1/4 h r. 1 1/2h r. 1 1/2 h r. 1 1/2 h r. 1 1 hr. 1 1 hr. I 1 hr. X 2 hrs. 1 2 hrs. 1 2 hrs. 1 4 hrs. X 4 hrs. X 4 hrs. I 8 hrs. 1 8 hrs. X 0 hrs. X 24 h r s . I 24 h r s . X 24 h r s . r.r. A nalysis (b)------- nnte Analyzed l g l jifi F /g blood. 7 /2 1 /8 1 ,c 7 /2 1 /8 1 ,c 7 /2 1 /8 1 ,c 7 /2 4 /8 1 ,c 7 /2 7 /8 1 ,c 7 /2 7 /8 1 ,c 7 /2 1 /8 1 ,c 7 /2 1 /8 1 ,c 7 /2 1 /8 1 ,p 23 28 17 8 .5 16 16 16 v.13 (e) M.6 2 Straight* Chain CB 73 73 73 76 75 76 78 78 (d ) 7 /2 8 /3 1 ,c 7 /2 8 /8 1 ,c 7 /2 8 /8 1 ,c 7 /2 4 /8 1 ,c 7 /2 4 /8 1 ,c 7 /2 4 /8 1 ,c 7 /2 8 /8 1 ,c 7 /2 8 /8 1 ,c 7 /2 8 /8 1 ,c 7 /2 3 /3 1 ,p 7 /2 0 /8 1 ,c 7 /2 3 /8 1 ,p 7 /2 0 /0 1 ,P 7 /2 0 /8 1 ,p 7 /2 0 /8 1 ,P 33 29 31 27 37 36 26 17 27 24 29 26 0.57 0 .4 5 1 .2 82 83 81 85 85 82 90 92 90 *" 91 TABLE 5 rnNf.ENTRATIAN OF PERFUMHmOCTAWOATB IN RAT BLOOQ SAMPLES ORAL nit&l Na . 81-2281 81-2282 81-2283 81-2234 Date Received 5/22/81 5/22/81 5/22/81 5/22/81 Dn eeaaIlggnnaattlioonn :t R at . Cr p , Recovery Time 302497 302498 302499 302500 IV 8 h r a . IV 8 hra. IV 8 h r a . IV 24 h r 8 . 81-2285 81-2286 81-2288 . 81-2289 81-2290 81-2344 5/22/81 5/22/81 5 /2 6 /8 1 _____ 5/26/81 5/26/81 5/29/81 302501 302502 303196 303197 303198 303223 [V tv I ..... I I V 24 h r a . 24 h ra . 168. h ra. 168 h ra . 168 h ra . 1/4 h r. 81-2345 ^ 81-2346 \ 81-2347 81-2348 % 81-2349 \ 81-2350 81-2351 81-2352 % >81-2353 I&1-2354 g. 1-2355 Q -2356 & -2357 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 5/29/31 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 303224 303225 303226 303227 303228 303229 303230 303231 303232 303233 303234 303235 303236 V 1/4 h r. V 1/2 h r. V . 1/2 h r. V 1/2 h r. V 1/4 h r. V 2 hra. V 2 hra. V 2 hra. V 4 hra. V 4 hra. V 4 hra. V 8 hra. V 8 hra. CC A n a ly s is (b) Date Analyzed 7 /2 3 /8 1 ,c 7 /2 3 /8 1 ,c 7 /2 3 /8 1 ,c 7 /2 0 /8 1 ,c 7 /2 0 /8 1 ,p 7 /2 2 /8 1 ,c 7 /2 1 /8 1 ,c 7/21/81,P 7 /2 1 /7 1 ,p 7 /1 6 /8 1 ,p 7/30/81p 7 /3 0 /8 1 ,c 7/30/81.C 7 /2 0 /8 1 ,c 7 /2 0 /8 1 ,c 7 /2 0 /8 1 ,c 7 /3 0 /8 1 ,c id) <d) (d) (d) (d) (d) 7 /3 0 /8 1 ,p 7 /2 0 /8 1 ,c 7 /2 0 /8 1 ,p X S traightlg F /g blogd Chaln^Cg------ 62 74 62 74 66 75 51 77 MB 45 77 53 76 ..Q..D52 .......... "-- 0.033 0.051 v 9 .5 (e ) % 9.8 24 29 22 25 18 -- 78 77 77 79 79 80 ** * 8 .6 M4 13 91 AIIWKM ^ rnMrPMTRATOH 0 PriPniOI>OOCTAHOTE IH R*T_gk SAMPLES, ORAL # di>81 fin . 81-2358 81-2359 81-2360 81-2361 81-2362 note Received 5/29/81 5/29/81 5/29/81 5/29/81 5/29/81 81-2363 5/29/81 81-2360 81-2550 81-2551 , 31-2552 to VO I 5/29/81 6/4/81 6 /4 /8 1 6 /4 /8 1 neslunation: 303237 303238 303239 303240 302503 302504 302505 303241 303242 303243 V 8 hrs. V 24 h r s . V 24 h r s . V 24 h r s . IV 168 h r s . IV 168 h r s . IV V V* 168 h rs . 168 h rs. 168 h rs 168 h r s . r.C A n a ly s is (b ) n n re A nalyzed j &l t Ml F/g..blogd 7 /2 0 /8 1 ,c 7 /2 0 /8 1 ,p 7 /1 6 /8 1 ,p 7 /2 0 /8 1 ,P 7 /1 6 /8 1 .P 7 /2 1 /8 1 .P 7 /2 2 /0 1 ,c M.5 18 0 .8 0 0.81 0.67 16 16 7/21/S l.p . -T /2 / 8T ,c' <\<28 W 7 /2 1 /8 1 ,P 7 /2 2 /8 1 ,c <\23 26 7 /2 7 /8 1 ,p 0.12 7/27 6 7 /3 1 /8 1 .P 0.12 7/27 6 7 /3 1 /8 1 ,P 0.058 Z S traightC haln C, 94 94 83 84 TaCA-CBl TABLE 3 Sample Designation 01 M" Group 1; f f * 1*9! 2\ ^ / t e f s i i g l i 0*08* Group I I ; ? "a l f ^ ' 150 mg/k g , s i n g l e d o se x'Group H I ; fe o a le c W / X S in g le d o ss a 5: u7 ,,t ,, :z >100*. Ti%r toutbd^ to" 25r ft i S . ^r S deviation of the nattod). ^ - 5* analytod i f n K .a o .ty . & - " r s " ' r i " " ir , e s t" d , Ii ________ _ ,,.Jot. alionots could 3 s r , -. -- - -* ^ ^ bc,, dried for 2SS S * -- a p p ro v e Cillaty an aly sis. Best e s . ~ 0 t" " - to t ^ standard in ck . iS ta ^ o n ^ J & la packed colon. o l d * y , T Doss nol contain TSCA CM Company Sanitized -3 0 - Group (b) Recovery Time Group I 25 mR/kg single dose, fem ale 1/4 h r. 1/2 h r. 1 hr. OiJ H* * a 2 hrs. 1rZ, &5- bo0 ^ b** oo 3. 3. 4 hrs. 3 hrs. (fl o 1 2149 8.5 2150 16 2151 Avg. 14 ppm 2152 16 2153 'v-l 2154 i d ...... Avg.' 16 ppm 2155 33 2156 29 2157 31 Avg. 31 ppm 2158 27 2159 37 2160 36 Avg. 33 ppm 2161 26 2162 17 2163 27 Avg. 23 ppm 2164 24 2165 29 2166 26 Avg. 26 ppm Group 11 2 .5 mg/kg single dose, fem ale - Group 111 150 mg/kg single dose, female - 2122 2 .7 2123 (c) 2124 2 J Avg. 2v8 ppm 2134 102 2135 162 2136 223 Avg 162 ppm 2125 (c) 2126 (c ) 2127 (c ) 2137 (c) 2138 (c) 2139 (c) 2128 (c) 2129 (c) 2130 (c) 2140 131 2141 178 2142 162 Avg. 157 ppm Group IV 25 mg/kg single dose, m ale ' 2146 23 2147 28 2148 17 -- Awgs--23-ppm V V Group V 25 mg/kg 11 d o s e s , Cernale 2344 9.8 2354 24 2349 18 Avg. 17 ppm 2346 29 2347 22 2348 25 A vg. -25-f i 2350 2351 2352 t 2353 2354 2355 (c) (c) (c) (c) (c) (c) 2281 62 2282 62 2283 66 Avg. 63 ppm 2356 8.6 2357 13 2358 18 Avg. 13 pnm TABLE 6 Bpfnverv Time 24 h r s . 2550 0.12 2551 0.12 2552 0.058 Avg. 0 .1 0 ppm I d e n ti f ic a t i o n I s by PRAL number. (b) The c o n tr o l group in T ab le 3 a p p lie s t o both (c) Samples d ried but not analyzed a t t h is tim e. `"18" 1" c a n t ' l iU te ` ' s " p U _ Company SsnUi^sd. D03S not contain TSCACB) m Rproverv Tiwe^ 1Ik h r. results fori TABLE 7 m PERCENT SLIGHT-CHAIN C0_ C jI Group H I Group lA^ _ 25 mgfkg Group V _ 25 mg/kB 8 hrs. Cothpan^ t??56 2357 91 2358 94_ Avg. 932 ,,tSCftCB CO RESULTS TADLE 7 !rnrP.nr STRAlGUT-CtlAItLCfl-iil Si ui (a) " U bv PRAL number. - - " " VZ&SS '= Company Sanitized. C c3 not contain TSCA CB) 81-2295 01-2296 81-2297 81-2298 81-2299 81-2300 31-2301 81-2302 81-2303 81-2304 81-2305 81-2324 81-2325 81-2326 81-2443 81-2444 81-2445 81-2446 81-2447 81-2448 81-2449 81-2450 31-2451 81-2452 81-2453 5/27/81 5/27/81 5/27/81 5/27/81 5/27/81 5/27/81 5/27/81 5/27/81 5/27/81 5/27/81 5/27/81 5/28/81 5/20/81 5/28/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 6/2/81 TAULb INHALATION 303245 303246 303247 303248 303249 303250 303251 303252 303253 303257 303258 303254 303255 3Q3256 303273 303274 303275 303277 303278 303279 303280 303281 303282 303283 303285 I I 1/2 h r. 11 1/2 h r . 11 2 h r s . II 2 hrs. 11 2 h r s . II 8 hrs. it 8 hrs. 11 8 h r s . c o n tro l c o n tro l 11 24 h r s . 11 24 h r s . 11 24 h r * . c o n tro l c o n tro l c o n tro l 111 1 /2 h r . III 2 hrs. I I I 1/2 h r. I I I 1/2 h r. 111 2 h r s . III 2 hrs. III 8 hrs. III 8 hrs. nc A nalysis Hate Analyzed 8 /3 /81,p 8 /3 /8 1 ,p 8 /3/81,p 8 /6/81,p 8/6/81,p 8 /6 /8 1 ,p 8 /6/81,p 87B/01.P 8/6/81,p 7/27/B l.p 7 /2 7 /8 1 ,P 7 /2 4 /8 1 ,p 7 /2 4 /8 1 .P 7 /2 4 /8 1 ,p 8/4/81,p 8/4/81,p 8/4/81,p 8 /5/81,p 0/6/81,p 8 /5/81,P 0 /5/81,P 8/6/81,p 8/6/81,p 8/5/81,P 8/5/81,p 1 .4 2 .2 1 .5 2 .1 0.79 0.99 0.76 n .d . n .d . 0.15 0 .1 0 0.16 . 0.09 0.04 0.04 9 .4 9.7 6 .0 6 .9 24 18 6 .1 2 .6 " -- * " " * " ' 90 86 89 3 r.ot contain TSCA CBl TABLE 8 CONCENTRATION OF PERFjl UOHOOCTANOATE IN HAT LOOP SAMPLES INHALATION m Sam ple (a ) PRAY N n . 81-2454 31-2455 81-2456 31-2457 81-2458 81-2459 81-2460 81-2461 81-2462 81-2463 81-2464 81-2465 81-2-466 81-2467 81-2463 01-2469 01-2470 81-2471 81-2472 81-2497 81-2498 01-2499 81-2500 81-2501 81-2502 Date Received 6 /2 /8 1 6 /2 /8 1 6 /2 /8 1 6 /2 /8 1 6 /2 /8 1 6 /2 /8 1 6 /2 /8 1 6 /2 /8 1 ........ . 6 /2 /8 1 6 /2 /8 1 6 /2 /8 1 6 /2 /8 1 6/2/81 6 /2 /8 1 6 /2 /8 1 6/2/81 6/2/81 6/2/81 6/2/81 6/3/81 6/3/81 6/3/81 6/3/81 6/3/81 6/3/01 D e siK n a tio n : R at t . C roup. R ecovery TI.a 303286 I l l 8 hr8. 303289 I 1/4 h r. 303290 1 1/4 h r. 303291 I 1/4 h r. 303292 I 1 hr. 303293 I 1/2 h r. 303294 1 1/2 h r. ............103295-. ....... ............ I - 1 / 2 -h r. 303296 1 2 hra. 303297 1 1 hr. 303298 I 1 hr. 303299 I 2 hra. 303300 1 2 hra. 303301 I 4 hra. 303302 I 4 hra. 303303 1 4 hra. 303304 1 8 hra. 303305 I 3 hra. 303306 1 8 hra. 303284 I I I 24 h r a . 303287 I I I 24 h r a . 303288 I I I 24 h ra . 303307 I 24 h r a . 303309 I 24 h r a . 303310 l 24 h r a . CC A n a ly s is (b)__________ _________________________ ' X S traight- D ate A nalyzed 1CQ1. UB P /g blood C hain Cfl 8/5/81,p 3 .9 -- 8 /1 2 /8 1 ,c 80 91 8 /1 2 /8 1 ,c 88 92 8 /1 2 /8 1 ,c 121 91 8 /1 1 /8 1 ,c 104 89 8/5/31,c 111 90 8/5/81,c 93 89 0/5/8iyC 124 8 /6/81,c 8 /1 1 /8 1 ,c 79 121 91 86 8/12/81.C 115 86 8 /6/81,c 50 93 8/6/81,c 8 /1 0 /8 1 ,c 78 77 92 95 8 /1 1 /8 1 ,c 8 /1 1 /8 1 ,c 69 60 93 92 8 /1 0 /8 1 ,c 60 90 8 /1 0 /8 1 ,c 43 92 8 /1 0 /8 1 ,c 111 91 7 /3 1 /8 1 ,p 0.64 - 7 /3 1 /8 1 ,p 0 .7 9 - 7 /3 1 /8 1 ,p 0.24 - 8 /3 /8 1 ,c 68 89 8/3/81,c 8 /3 /8 1 .c 42 46 90 88 Company Sanitized- Does not contain t sc a c a i Sample (a) PRAL No . n ate Received 81-2503 6/3/81 81-2504 6/3/81 81-2505 6/3/81 81-2506 6/3/81 81-2507 6/3/81 81-2508 6/3/81 81-2509 6/3/81 81-2510 6/3/81 81-2511 81-2512 6 /3 /8 1 6 /3 /8 1 81-2513 6/3/81 81-2523 6 /4 /8 1 81-2524 6/4/81 81-2525 6 /4 /8 1 81-2526 6/4/81 81-2527 6/4/81 81-2594 6/9/81 81-2595 6/9/81 81-2596 6/9/81 81-2597 6/9/81 81-2598 6/9/01 INHALATION ff---------- I . c r o r . e c o v e r z .l l a s 303794 303795 control control 303797 303798 303799 303810 303811 303812 303813 303816 303908 303909 303817 303818 303819 303308 303311 303312 303263 303261 IV 2 h r s . IV 1 /2 h r . IV 1 /2 h r . IV 2 h r s . IV 2 h r s . IV 8 h r s . IV 8 h r s . IV 8 h r s . c o n tro l c o n tro l IV IV IV I I 1 24 h rs . 24 h r s . 24 h r s . 168 h r s . 168 h r s . 168 h r s . c o n tro l c o n tro l r.c A n a ly sis ( b j n a te A nalyzed fr gl V8 F /g blood 8 /4 /01,p 0.19 (c) 8 /4 /8 1 ,p 0.11 8 /6 /8 1 ,c 118 8 /7 /8 1 ,c 153 8 /7 /8 1 ,p 131 8 /7 /8 1 .C 163 8 /7 /8 1 .C 203 8 /7 /8 1 ,c 114 8 /1 2 /8 1 ,0 177 8 /1 3 /8 1 ,c 198 8 /1 3 /8 1 ,0 170 8 /6/81,p n .d . 8 /6 /8 1 ,p n .d . 8 /6 /8 1 ,c 143 8 /6 /8 1 ,0 148 8 /6 /8 1 ,c : 151 7 /2 7 /8 1 ,P 1.1 7 /2 7 /8 1 ,p 0 .5 4 7/27/81,p 0 .5 1 8 /7/81,p n.d. 8 /7/81,p n .d . X S tralghtC haln CQ 76 76 76 75 77 75 80 79 79 83 80 82 Company Sanitized. Doss net contain TSCA CUT TABLE 8 (a) Sample Designation for Inhalation Group I ; fem ales, 10 mg/ 3 Group I I ; fem ales, 0 . 1 mg/m 3 Group I I I ; female* 1.0 mg/m " 'G ro u p IV; m ales, 10 mg/m vsztZi'Sszz(b) CC d=.=rib.d in t * U 1. S S t o th* 1M r,laclv' deviation of the method). (c) S w -- ," i8 h t " " 4 Company Sanitize;!. Coca no! contain TSCA CBJ -38- Recovery Time 1/4 h r. 1/2 h r. 1 hr. ui> I 2 hrs 4 hrs TABLE 9 RESULTS FORI UB F /b (a ) Group I 10 mg/m^, fem ale Group I I -- J0 .1; mg7/m7 fm ale___ Group I I I 1 .0 mg/m female 2455 80 2456 88 2457 121 Avg. 96 ppm 2459 111 2460 93 2461 124 Avg. 109 ppm 2295 1.8 2296 2. 2 2297 1 .4 Avg. 1 .8 ppm 2446 9.4 2448 6.0 2449 6 .9 Avg. 7 .4 ppm 2463 121 2464 115 2458 104 Avg. 113 ppm 2462 79 2465 50 2466 78 Avg. 69 ppm 2298 2 .2 2299 1 .5 2300 2.1 Avg. 1 .9 ppm 2447 9.7 2450 24 2451 18_ Avg. 17 ppm 2467 77 2468 69 2469 60 Avg. 69 ppm V V C o n tro l 2304 2305 2443 2444 n .d . n .d . 0.09 0.04 ppm 2445 2503 2504 2523 0.04 0.19 0.11 A .d . 2524 n .d . 2597 n .d . 2598 n .d . : r.oi contain TSCA CSt Company SanUs sd, Dos--4 # 8 hrs. Group 1 10 m g /ra \ female 2470 60 2471 43 2472 111 Avg. 71 ppm G TABLE 9 RESULTS F O R ^ I Jsl Group 11 0 .1 mg/m fem ale 2301 0.79 2302 0.99 2303 0.76 Avg. 0 .8 5 ppm Group 111 1 .0 mg/m fem ale 2452 6.1 2453 2.6 2454 3j9 Avg. 4 .2 ppm Group IV 10 mg/m3 m ale 2511 177 2512 198 2513 HO Avg. 182 ppa V V C o n tro l 24 h r s . 2500 68 2501 42 2502 46 Avg. 52 ppm 2324 0.15 2325 0 .10 2326 0.16 Avg. 0 .1 4 ppm 2497 0.64 2498 0.79 2499 0.24 Avg. 0 .5 6 ppm 2525 143 2526 148 2527 151 Avg. 147 ppm 16B h r s . 2594 0 .1 1 2595 0.54 2596 0 .5 1 Avg. 0 .3 9 ppm I (a ) R e s u lts from T able B, a rra n g e d by groi and tim e w ith a v e ra g e s f o r each s e t o f th r e e . As noted t h e r e , v a lu e s > 100 Bhould be rounded to two s ig n if ic a n t f ig u r e s . Sample i d e n t i f ic a t io n i s by PRAL number. Sand -rV l ;oes Co'rTi? ar^' ordain t s c a c Recovery Time, 1/4 h r. 1/2 h r. 1 hr. i 2 hrs. 4 hrs. 8 hrs. TABLE 10 RESULTS FOR | | PERCENT STRA1CHT-CHAIN Cp 5-- Group I 10 mg/m fem ale __ Croup I I 0 .1 mg/m fem ale Group I H 1 .0 mg/m female Group IV 10 mg/mm ale____ 2455 91 2456 92 2457 91 Avg. 91% 1 2459 90 1 2460 89 1 246191 1 Avg. 90% 1 2463 86 2464 86 2458. 89 1 Avg. 87% 1 2462 91 2465 93 2466 92 | Avg. 92% 2467 95 2468 93 2469 92 Avg. 93% 2470 90 2471 92 2472 91 Avg. 91% 2295 2296 2297 - 12298 2299 12300 - 2301 2302 2303 2446 90 2448 86 1 2449 89 I Avg. 88% 2505 76 2507 76 1 2508 75^ I Avg. 76* | 2447 2450 - 2451 - 1 2506 76 2509 77 2510 25 1 Avg. 76% 2452 2453 2454 - 2511 80 2512 79 2513 79 Avg. 79% C o n tro l 81-2304 -2305 -2443 -2444 -2445 -2503 1 -2504 1 -2524 -2597 -2598 1 1 1 _ __ i -.T S C A C B i I Rppnvprv Time 24 h r s . 168 h r s . RESULTS jFOR TABLE AO 3 PERCENT STRAICHT-CUAIN Cfl (a) G---r-o-u- p--1=-- 3-- 10 mg/m , fem ale Group I I J 0 .1 mg/m female Group I I I 1 .0 mg/m female Group IV 10 mg/m* m ale 2500 89 2501 90 2502 88 Avg. 88Z 2324 2325 2326 - 2497 2498 95 2499 - 2525 83 2526 80 2527 82 Avg. B2Z 2594 2595 2596 - - - - C ontrol i i* (a ) R e s u lts from T ab le 8 f o r c a p i l l a r y column a n a ly s e s , i n w hich t h e d i s t r i b u t i o n o f Cg iso m ers ( s tr a ig h t- c h a in and 4 branched isom ers) i s determ ined along w ith th ; c o n c e n tra tio n . Sample i d e n t i f i c a t i o n i s by PRAL number. , ini a \ n T S C A ^ noieo' s.waoes C om paq